anti-KLK2 CAR T cells JNJ-75229414

A preparation of T lymphocytes that have been genetically modified to express a chimeric antigen receptor (CAR) targeting human kallikrein-2 (hK2; KLK2) expressed on tumor cells, with potential immunostimulating and antineoplastic activities. Upon administration, anti-KLK2 CAR T cells JNJ-75229414 target and bind to KLK2-expressing tumor cells, thereby inducing selective toxicity in KLK2-expressing tumor cells. KLK2 is overexpressed in certain tumors, including prostate adenocarcinoma.